Kangchen Pharmaceuticals: Presenting preclinical research data for two innovative drugs at the 2026 AACR Annual Meeting.

Kang Chen Pharmaceuticals announced that on April 21, 2026, at the AACR Annual Meeting, they presented the preclinical research data of the innovative anti-tumor drugs "KC1086" and "KC1101" in poster form. KC1086 has strong inhibitory activity and high selectivity against KAT6A/B and KAT7. Phase I clinical trials have been initiated and have received approval from the US FDA for new drug clinical studies. KC1101 is a selective small molecule inhibitor of TACC3, with strong anti-tumor proliferation activity. Preclinical research is progressing in an orderly manner, and the company plans to submit a new drug clinical trial application in 2026. There is uncertainty in pharmaceutical research and development, and this development will not have a significant impact on the company's performance in the near term.